Progression of Precision Statin Prescribing for Reduction of Statin-Associated Muscle Symptoms

References

• Klimchak AC , PatelMY , IorgaŞR , KulkarniN , WongND. Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States. Am. J. Prev. Cardiol.1(1), 100010 (2020).
   PubMedGoogle Scholar
• Gu Q , Paulose-RamR , BurtVL , KitBK. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012. NCHS Data BriefDec(177), 1–8 (2014).
   Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration , BaigentC , BlackwellLet al.Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet376(9753), 1670–1681 (2010).
   PubMed Web of Science ®Google Scholar
• Arnett DK , BlumenthalRS , AlbertMAet al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation140(11), 596–646 (2019).
   PubMed Web of Science ®Google Scholar
• Statin use for the primary prevention of cardiovascular disease in adults: recommendation statement. Am. Fam. Physician95(2), 108A–108G (2017).
   Google Scholar
• Stancu C , SimaA. Statins: mechanism of action and effects. J Cell Mol Med.5(4), 378–387 (2001).
   PubMed Web of Science ®Google Scholar
• Armitage J . The safety of statins in clinical practice. Lancet370(9601), 1781–1790 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenson RS , BakerSK , JacobsonTA , KopeckySL , ParkerBA. The National Lipid Association’s Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J. Clin. Lipidol.8(Suppl. 3), S58–S71 (2014).
   PubMed Web of Science ®Google Scholar
• Chatzizisis YS , KoskinasKC , MisirliG , VaklavasC , HatzitoliosA , GiannoglouGD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf.33(3), 171–187 (2010).
   PubMed Web of Science ®Google Scholar
• Chowdhury R , KhanH , HeydonEet al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur. Heart J.34(38), 2940–2948 (2013).
   PubMed Web of Science ®Google Scholar
• Hamelin BA , TurgeonJ. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci.19(1), 26–37 (1998).
   PubMed Web of Science ®Google Scholar
• Vaklavas C , ChatzizisisYS , ZiakasA , ZamboulisC , GiannoglouGD. Molecular basis of statin-associated myopathy. Atherosclerosis202(1), 18–28 (2009).
   PubMed Web of Science ®Google Scholar
• Ramsey LB , JohnsonSG , CaudleKEet al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin. Pharmacol. Ther.96(4), 423–428 (2014).
   PubMed Web of Science ®Google Scholar
• Guan ZW , WuKR , LiRet al. Pharmacogenetics of statins treatment: efficacy and safety. J. Clin. Pharm. Ther.44(6), 858–867 (2019).
   PubMed Web of Science ®Google Scholar
• Heyes N , KapoorP , KerrID. Polymorphisms of the multidrug pump ABCG2: a systematic review of their effect on protein expression, function, and drug pharmacokinetics. Drug Metab. Dispos.46(12), 1886–1899 (2018).
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoff RM , NiemiM , RamseyLBet al. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms. Clin. Pharmacol. Ther.111(5), 1007–1021 (2022).
   PubMed Web of Science ®Google Scholar
• Maxwell WD , RamseyLB , JohnsonSGet al. Impact of pharmacogenetics on efficacy and safety of statin therapy for dyslipidemia. Pharmacotherapy37(9), 1172–1190 (2017).
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-ongoing-safety-review-high-dose-zocor-simvastatin-and-increased-risk#:∼:text=%5B3%2D19%2D2010%5D,*%20(simvastatin)%2080%20mg%2C
   Google Scholar
• Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group . Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomized trial. Lancet376(9753), 1658–1669 (2010).
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: new restrictions, contraindications, and dose limitations of Zocor (simvastatin) to reduce the risk of muscle injury. www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor
   Google Scholar
• The SEARCH Collaborative Group , LinkE , ParishSet al.SLCO1B1 variants and statin-induced myopathy – a genome-wide study. N. Engl. J. Med.359(8), 789–799 (2008).
   PubMed Web of Science ®Google Scholar
• USFDA drug safety communication: revised dose limitation for Zocor (simvastatin) when taken with amiodarone. www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-dose-limitation-zocor-simvastatin-when-taken-amiodarone
   Google Scholar
• USFDA Table of Pharmacogenetic Associations. www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1
   Google Scholar
• Voora D , ShahSH , SpasojevicIet al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol.54(17), 1609–1616 (2009).
   PubMed Web of Science ®Google Scholar
• Ramsey LB , JohnsonSG , CaudleKEet al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin. Pharmacol. Ther.96(4), 423–428 (2014).
   PubMed Web of Science ®Google Scholar
• Grundy SM , StoneNJ , BaileyALet al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol.73(24), 3168–3209 (2019).
   PubMed Web of Science ®Google Scholar
• Hirvensalo P , TornioA , NeuvonenMet al. Enantiospecific pharmacogenomics of fluvastatin. Clin. Pharmacol. Ther.106(3), 668–680 (2019).
   PubMed Web of Science ®Google Scholar
• Royal Dutch Pharmacists Association – Dutch Pharmacogenetics Working Group. www.g-standaard.nl/risicoanalyse/B0004055.PDF
   Google Scholar
• Gislason GH , RasmussenJN , AbildstrømSZet al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarctions. Eur. Heart J.27(10), 1153–1158 (2006).
   PubMed Web of Science ®Google Scholar
• Blackburn D , DobsonRT , BlackburnJL , WilsonTW , StangMR , SemchukWM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can. J. Cardiol.21(6), 485–488 (2005).
   PubMed Web of Science ®Google Scholar
• Vinci P , PanizonE , TosoniLMet al. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int. J. Mol. Sci.22(21), 11687 (2021).
   PubMed Web of Science ®Google Scholar
• MEPS prescribed medicines file. The top 300 drugs of 2019. https://clincalc.com/DrugStats/Top300Drugs.aspx
   Google Scholar
• Fuentes AV , PinedaM , VenkataKCN. Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training, and practice. Pharmacy (Basel)6(2), 43 (2018).
   PubMedGoogle Scholar
• Zhang H , PlutzkyJ , SkentzosSet al. Discontinuation of statins in routine care settings: a cohort study. Ann. Intern. Med.158(7), 526–534 (2013).
   PubMed Web of Science ®Google Scholar
• Hope HF , BinkleyGM , FentonS , KitasGD , VerstappenSMM , SymmonsDPM. Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS One14(1), e0201196 (2019).
   PubMed Web of Science ®Google Scholar
• Morotti K , LopezJ , VaupelV , SwislockiA , SiegelD. Adherence to and persistence with statin therapy in a veteran population. Ann. Pharmacother.53(1), 43–49 (2019).
   PubMed Web of Science ®Google Scholar
• Lewey J , ShrankWH , BowryAD , KilabukE , BrennanTA , ChoudhryNK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am. Heart J.165(5), 665–78678.e1 (2013).
   PubMed Web of Science ®Google Scholar
• De Vera MA , BholeV , BurnsLC , LacailleD. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br. J. Clin. Pharmacol.78(4), 684–698 (2014).
   PubMed Web of Science ®Google Scholar
• Korhonen MJ , RuokoniemiP , IlomäkiJ , MeretojaA , Helin-SalmivaaraA , HuupponenR. Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes. Pharmacoepidemiol. Drug Saf.25(2), 161–169 (2016).
   PubMed Web of Science ®Google Scholar
• Reston JT , BueltA , DonahueMP , NeubauerB , VagichevE , McSheaK. Interventions to improve statin tolerance and adherence in patients at risk for cardiovascular disease: a systematic review for the 2020 U.S. Department of Veterans Affairs and US Department of Defense Guidelines for Management of Dyslipidemia. Ann. Intern. Med.173(10), 806–812 (2020).
   PubMed Web of Science ®Google Scholar
• Putt ME , ReesePP , VolppKGet al. The Habit Formation trial of behavioral economic interventions to improve statin use and reduce the risk of cardiovascular disease: rationale, design and methodologies. Clin. Trials16(4), 399–409 (2019).
   PubMed Web of Science ®Google Scholar
• Christian C , BordenBA , DanaheyKet al. Pharmacogenomic-based decision support to predict adherence to medications. Clin. Pharmacol. Ther.108(2), 368–376 (2020).
   PubMed Web of Science ®Google Scholar
• Malki MA , PearsonER. Drug–drug–gene interactions and adverse drug reactions. Pharmacogenomics J.20(3), 355–366 (2020).
   PubMed Web of Science ®Google Scholar
• Božina N , GanociL , SimičevićLet al. Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review. Arh. Hig. Rada. Toksikol.72(3), 114–128 (2021).
   PubMedGoogle Scholar
• Chang TS , BuchipudiA , FonarowGC , PfefferMA , SingerJS , ChengEM. Physicians voluntarily using an EHR-based CDS tool improved patients’ guideline-related statin prescription rates: a retrospective cohort study. Appl. Clin. Inform.10(3), 421–445 (2019).
   PubMed Web of Science ®Google Scholar
• Adusumalli S , WestoverJE , JacobyDSet al. Effect of passive choice and active choice interventions in the electronic health record to cardiologists on statin prescribing: a cluster randomized clinical trial. JAMA Cardiol.6(1), 40–48 (2021).
   PubMed Web of Science ®Google Scholar
• Liu M , Vnencak-JonesCL , RolandBPet al. A tutorial for pharmacogenomics implementation through end-to-end clinical decision support based on ten years of experience from PREDICT. Clin. Pharmacol. Ther.109(1), 101–115 (2021).
   PubMed Web of Science ®Google Scholar
• Hicks JK , DunnenbergerHM , GumpperKF , HaidarCE , HoffmanJM. Integrating pharmacogenomics into electronic health records with clinical decision support. Am. J. Health Syst. Pharm.73(23), 1967–1976 (2016).
   PubMed Web of Science ®Google Scholar
• Wojtyniak JG , SelzerD , SchwabM , LehrT. Physiologically based precision dosing approach for drug–drug–gene interactions: a simvastatin network analysis. Clin. Pharmacol. Ther.109(1), 201–211 (2021).
   PubMed Web of Science ®Google Scholar
• Newman CB , PreissD , TobertJAet al. American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb. Vasc. Biol.39(2), e38–e81 (2019). Erratum in: Arterioscler Thromb Vasc Biol. 2019 May;39(5).
   PubMed Web of Science ®Google Scholar
• Mancini GB , BakerS , BergeronJet al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group update. Can J Cardiol.32(Suppl. 7), S35–65 (2016).
   PubMed Web of Science ®Google Scholar
• Stroes ES , ThompsonPD , CorsiniAet al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management. Eur Heart J.36(17), 1012–22 (2015).
   PubMed Web of Science ®Google Scholar